Literature DB >> 19814621

Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients.

José Medrano1, Pablo Barreiro, Salvador Resino, Paula Tuma, Violeta Rodríguez, Eugenia Vispo, Pablo Labarga, Antonio Madejón, Javier García-Samaniego, Inmaculada Jiménez-Nácher, Luz Martín-Carbonero, Vincent Soriano.   

Abstract

Information on the rate and timing of hepatitis C virus (HCV) relapse after treatment with pegylated interferon plus ribavirin is scarce. Among 604 patients treated for chronic hepatitis C, the 386 who were human immunodeficiency virus (HIV) positive attained an end-of-treatment response less frequently and experienced relapse more often than did the 218 who were HIV negative. However, episodes of HCV relapse occurred before week 12 in most cases, regardless of HIV status.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19814621     DOI： 10.1086/630205

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  14 in total

Review 1.  After the cure: management of HCV after achievement of SVR.

Authors:  Zachary A Zator; Raymond T Chung
Journal:  Curr HIV/AIDS Rep       Date:  2013-12       Impact factor: 5.071

2.  Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir.

Authors:  Kevin P Vo; Philip Vutien; Matthew J Akiyama; Vinh D Vu; Nghiem B Ha; Joy I Piotrowski; James Wantuck; Marina M Roytman; Naoky Tsai; Ramsey Cheung; Jiayi Li; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2015-03-28       Impact factor: 3.199

3.  Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

Authors:  Norma I Rallón; Susanna Naggie; José M Benito; José Medrano; Clara Restrepo; David Goldstein; Kevin V Shianna; Eugenia Vispo; Alex Thompson; John McHutchison; Vincent Soriano
Journal:  AIDS       Date:  2010-05-15       Impact factor: 4.177

4.  IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.

Authors:  Norma I Rallón; Vincent Soriano; Susanna Naggie; Clara Restrepo; David Goldstein; Eugenia Vispo; John McHutchison; José M Benito
Journal:  AIDS       Date:  2011-05-15       Impact factor: 4.177

5.  Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.

Authors:  A Rivero-Juarez; J A Mira; A Camacho; K Neukam; I Perez-Camacho; A Caruz; J Macias; J Torre-Cisneros; J A Pineda; A Rivero
Journal:  Infection       Date:  2012-10-14       Impact factor: 3.553

6.  Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection.

Authors:  Jun Hou; Gertine van Oord; Zwier M A Groothuismink; Mark A A Claassen; Kim Kreefft; Fatiha Zaaraoui-Boutahar; Wilfred F J van IJcken; Albert D M E Osterhaus; Harry L A Janssen; Arno C Andeweg; Robert J de Knegt; Andre Boonstra
Journal:  J Virol       Date:  2014-08-06       Impact factor: 5.103

7.  Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry.

Authors:  Marina Roytman; Resham Ramkissoon; Christina Wu; Leena Hong; Ruby Trujillo; Leslie Huddleston; Peter Poerzgen; Todd Seto; Linda Wong; Naoky Tsai
Journal:  Hepatol Int       Date:  2016-03-30       Impact factor: 6.047

8.  Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea.

Authors:  Suh Yoon Yang; Hyun Woong Lee; Youn Jae Lee; Sung Jae Park; Ki Young Yoo; Hyung Joon Kim
Journal:  Clin Mol Hepatol       Date:  2015-06-26

9.  Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs.

Authors:  Claudia Minosse; Cesare E M Gruber; Martina Rueca; Chiara Taibi; Mauro Zaccarelli; Elisabetta Grilli; Marzia Montalbano; Maria R Capobianchi; Andrea Antinori; Gianpiero D'Offizi; Fiona McPhee; Anna Rosa Garbuglia
Journal:  Viruses       Date:  2021-06-16       Impact factor: 5.048

Review 10.  Treatment outcomes of treatment-naïve Hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts.

Authors:  Anna Davies; Kasha P Singh; Zara Shubber; Philipp Ducros; Edward J Mills; Graham Cooke; Nathan Ford
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.